GIPR and obesity due to melanocortin 4 receptor deficiency: While these features are associated with a LoF phenotype, other studies suggest that both GIPR agonists and antagonists may provide benefits to T2D and obesity (Yang et al., 2022), indicating a complex mechanism of GIPR action within the processes of blood glucose and weight regulation.